Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
0xbwx6nzPUsY6Fbc
